<meta http-equiv="Content-Type" content="text/html; charset=utf-8"><link type="text/css" rel="stylesheet" href="resources/sheet.css" >
<style type="text/css">.ritz .waffle a { color: inherit; }.ritz .waffle .s0{background-color:#ffffff;text-align:left;font-weight:bold;text-decoration:underline;-webkit-text-decoration-skip:none;text-decoration-skip-ink:none;color:#000000;font-family:'Arial';font-size:10pt;vertical-align:bottom;white-space:normal;overflow:hidden;word-wrap:break-word;direction:ltr;padding:2px 3px 2px 3px;}.ritz .waffle .s3{background-color:#ffffff;text-align:left;font-weight:bold;color:#000000;font-family:'Arial';font-size:10pt;vertical-align:bottom;white-space:normal;overflow:hidden;word-wrap:break-word;direction:ltr;padding:2px 3px 2px 3px;}.ritz .waffle .s7{background-color:#ffffff;text-align:left;font-weight:bold;color:#000000;font-family:'Arial';font-size:10pt;vertical-align:bottom;white-space:nowrap;direction:ltr;padding:2px 3px 2px 3px;}.ritz .waffle .s6{border-left: none;border-right: none;background-color:#ffffff;text-align:left;color:#000000;font-family:'Arial';font-size:10pt;vertical-align:bottom;white-space:nowrap;direction:ltr;padding:2px 3px 2px 3px;}.ritz .waffle .s2{background-color:#ffffff;text-align:left;color:#000000;font-family:'Arial';font-size:10pt;vertical-align:bottom;white-space:normal;overflow:hidden;word-wrap:break-word;direction:ltr;padding:2px 3px 2px 3px;}.ritz .waffle .s5{border-left: none;background-color:#ffffff;text-align:left;color:#000000;font-family:'Arial';font-size:10pt;vertical-align:bottom;white-space:nowrap;direction:ltr;padding:2px 3px 2px 3px;}.ritz .waffle .s1{background-color:#ffffff;text-align:left;color:#000000;font-family:'Arial';font-size:10pt;vertical-align:bottom;white-space:nowrap;direction:ltr;padding:2px 3px 2px 3px;}.ritz .waffle .s4{border-right: none;background-color:#ffffff;text-align:left;color:#000000;font-family:'Arial';font-size:10pt;vertical-align:bottom;white-space:nowrap;direction:ltr;padding:2px 3px 2px 3px;}</style><div class="ritz grid-container" dir="ltr"><table class="waffle" cellspacing="0" cellpadding="0"><thead><tr><th class="row-header freezebar-origin-ltr"></th><th id="1499313419C0" style="width:814px;" class="column-headers-background">A</th><th id="1499313419C1" style="width:305px;" class="column-headers-background">B</th><th id="1499313419C2" style="width:100px;" class="column-headers-background">C</th><th id="1499313419C3" style="width:100px;" class="column-headers-background">D</th></tr></thead><tbody><tr style="height: 20px"><th id="1499313419R0" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">1</div></th><td class="s0" dir="ltr">Atypical Hyperplasia</td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr">Source </td><td class="s1" dir="ltr">GTG 67</td></tr><tr style="height: 20px"><th id="1499313419R1" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">2</div></th><td class="s2" dir="ltr"></td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td></tr><tr style="height: 20px"><th id="1499313419R2" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">3</div></th><td class="s2" dir="ltr">Summary:</td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td></tr><tr style="height: 20px"><th id="1499313419R3" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">4</div></th><td class="s2" dir="ltr">Risk of progression ~ 40%<br> <br>If declines surgery:<br>Explain risks<br>Consider imaging to rule out invasive Ca, d/w MDT<br>Advise IUS, 2nd line continuous oral progestogens<br>3-monthly endometrial surveillance until 2 consecutive negative samples<br>Histological disease regression = 2 consecutive negative samples <br>If has histo disease regression, long-term f/u is 6-12 month bx until hysterectomy<br>If desires fertility, advise at least 1 negative sample prior to conception AND refer to fertility<br></td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td></tr><tr style="height: 20px"><th id="1499313419R4" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">5</div></th><td class="s2" dir="ltr"></td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td></tr><tr style="height: 20px"><th id="1499313419R5" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">6</div></th><td class="s2" dir="ltr"></td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td></tr><tr style="height: 20px"><th id="1499313419R6" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">7</div></th><td class="s2" dir="ltr"></td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td></tr><tr style="height: 20px"><th id="1499313419R7" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">8</div></th><td class="s2" dir="ltr"></td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td></tr><tr style="height: 20px"><th id="1499313419R8" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">9</div></th><td class="s3" dir="ltr">Major Risk Factors</td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td></tr><tr style="height: 20px"><th id="1499313419R9" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">10</div></th><td class="s2" dir="ltr">Oestragen (HRT)</td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td></tr><tr style="height: 20px"><th id="1499313419R10" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">11</div></th><td class="s2" dir="ltr">Tamoxifen</td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td></tr><tr style="height: 20px"><th id="1499313419R11" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">12</div></th><td class="s2" dir="ltr">PCOS</td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td></tr><tr style="height: 20px"><th id="1499313419R12" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">13</div></th><td class="s2" dir="ltr">Obesity</td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td></tr><tr style="height: 20px"><th id="1499313419R13" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">14</div></th><td class="s2" dir="ltr">Immunosuppression (transplant)</td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td></tr><tr style="height: 20px"><th id="1499313419R14" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">15</div></th><td class="s2" dir="ltr"></td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td></tr><tr style="height: 20px"><th id="1499313419R15" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">16</div></th><td class="s3" dir="ltr"></td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td></tr><tr style="height: 20px"><th id="1499313419R16" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">17</div></th><td class="s3" dir="ltr">Atypical Hyperplasia Key Points</td><td class="s1"></td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td></tr><tr style="height: 20px"><th id="1499313419R17" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">18</div></th><td class="s2" dir="ltr">Total hysterectomy indicated as risk of underlying malignancy or progression to cancer (studies show progression rates are 30-50%)</td><td class="s1" dir="ltr">Risk of progression ~ 40%</td><td class="s4 softmerge" dir="ltr"><div class="softmerge-inner" style="width:198px;left:-1px">Risk of progression ~ 40%<br></div></td><td class="s5" dir="ltr"></td></tr><tr style="height: 20px"><th id="1499313419R18" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">19</div></th><td class="s2" dir="ltr">IUS or oral progesterones alternatives for women who decline surgery.</td><td class="s1" dir="ltr"> </td><td class="s1" dir="ltr"> <br></td><td class="s1" dir="ltr"></td></tr><tr style="height: 20px"><th id="1499313419R19" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">20</div></th><td class="s2"></td><td class="s1"></td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td></tr><tr style="height: 20px"><th id="1499313419R20" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">21</div></th><td class="s3" dir="ltr">EH with atypia but declines / unsuitable for hysterectomy</td><td class="s1" dir="ltr">If declines surgery:</td><td class="s4 softmerge" dir="ltr"><div class="softmerge-inner" style="width:198px;left:-1px">If declines surgery:<br></div></td><td class="s5" dir="ltr"></td></tr><tr style="height: 20px"><th id="1499313419R21" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">22</div></th><td class="s2" dir="ltr">Explain risks</td><td class="s1" dir="ltr">Explain risks</td><td class="s1" dir="ltr">Explain risks<br></td><td class="s1" dir="ltr"></td></tr><tr style="height: 20px"><th id="1499313419R22" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">23</div></th><td class="s2" dir="ltr">Consider imaging to rule out invasive Ca, d/w MDT</td><td class="s2" dir="ltr">Consider imaging to rule out invasive Ca, d/w MDT</td><td class="s4 softmerge" dir="ltr"><div class="softmerge-inner" style="width:298px;left:-1px">Consider imaging to rule out invasive Ca, d/w MDT<br></div></td><td class="s6" dir="ltr"></td></tr><tr style="height: 20px"><th id="1499313419R23" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">24</div></th><td class="s2" dir="ltr">Advise IUS, 2nd line continuous oral progestogens</td><td class="s2" dir="ltr">Advise IUS, 2nd line continuous oral progestogens</td><td class="s4 softmerge" dir="ltr"><div class="softmerge-inner" style="width:398px;left:-1px">Advise IUS, 2nd line continuous oral progestogens<br></div></td><td class="s6" dir="ltr"></td></tr><tr style="height: 20px"><th id="1499313419R24" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">25</div></th><td class="s2" dir="ltr">3-monthly endometrial surveillance until 2 consecutive negative samples</td><td class="s2" dir="ltr">3-monthly endometrial surveillance until 2 consecutive negative samples</td><td class="s4 softmerge" dir="ltr"><div class="softmerge-inner" style="width:498px;left:-1px">3-monthly endometrial surveillance until 2 consecutive negative samples<br></div></td><td class="s6" dir="ltr"></td></tr><tr style="height: 20px"><th id="1499313419R25" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">26</div></th><td class="s2" dir="ltr">In asymptomatic women with a uterus and evidence of histological disease regression, based upon a minimum of two consecutive negative endometrial biopsies, long-term follow-up with endometrial biopsy every 6–12 months is recommended until a hysterectomy is performed.</td><td class="s1 softmerge" dir="ltr"><div class="softmerge-inner" style="width:302px;left:-1px">Histological disease regression = 2 consecutive negative samples </div></td><td class="s4 softmerge" dir="ltr"><div class="softmerge-inner" style="width:398px;left:-1px">Histological disease regression = 2 consecutive negative samples <br></div></td><td class="s6" dir="ltr"></td></tr><tr style="height: 20px"><th id="1499313419R26" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">27</div></th><td class="s2" dir="ltr">If desires fertility - advise at least 1 negative sample prior to conception, refer to fertility specialist</td><td class="s1 softmerge" dir="ltr"><div class="softmerge-inner" style="width:302px;left:-1px">If has histo disease regression, long-term f/u is 6-12 month bx until hysterectomy</div></td><td class="s4 softmerge" dir="ltr"><div class="softmerge-inner" style="width:498px;left:-1px">If has histo disease regression, long-term f/u is 6-12 month bx until hysterectomy<br></div></td><td class="s6" dir="ltr"></td></tr><tr style="height: 20px"><th id="1499313419R27" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">28</div></th><td class="s2"></td><td class="s1 softmerge" dir="ltr"><div class="softmerge-inner" style="width:302px;left:-1px">If desires fertility, advise at least 1 negative sample prior to conception AND refer to fertility</div></td><td class="s4 softmerge" dir="ltr"><div class="softmerge-inner" style="width:598px;left:-1px">If desires fertility, advise at least 1 negative sample prior to conception AND refer to fertility<br></div></td><td class="s6" dir="ltr"></td></tr><tr style="height: 20px"><th id="1499313419R28" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">29</div></th><td class="s3" dir="ltr">HRT</td><td class="s1"></td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td></tr><tr style="height: 20px"><th id="1499313419R29" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">30</div></th><td class="s2" dir="ltr">If taking sequential HRT, advise continuous progestogen, particularly IUS</td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td></tr><tr style="height: 20px"><th id="1499313419R30" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">31</div></th><td class="s2"></td><td></td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td></tr><tr style="height: 20px"><th id="1499313419R31" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">32</div></th><td class="s2"></td><td></td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td></tr><tr style="height: 20px"><th id="1499313419R32" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">33</div></th><td class="s3" dir="ltr">All hysterectomies (with / without atypia)</td><td></td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td></tr><tr style="height: 20px"><th id="1499313419R33" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">34</div></th><td class="s2" dir="ltr">NB: advise BSO if postmenopausal to all women having hysterectomy, offer BS if premenopausal</td><td></td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td></tr><tr style="height: 20px"><th id="1499313419R34" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">35</div></th><td class="s2" dir="ltr"></td><td></td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td></tr><tr style="height: 20px"><th id="1499313419R35" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">36</div></th><td class="s3" dir="ltr">Type of hyperplasia</td><td class="s7" dir="ltr">Progression Rate</td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td></tr><tr style="height: 20px"><th id="1499313419R36" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">37</div></th><td class="s2" dir="ltr">EH without atypia (overall)</td><td class="s1" dir="ltr">&lt;5%</td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td></tr><tr style="height: 20px"><th id="1499313419R37" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">38</div></th><td class="s2" dir="ltr">Simple EH without atypia</td><td class="s1" dir="ltr">1%</td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td></tr><tr style="height: 20px"><th id="1499313419R38" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">39</div></th><td class="s2" dir="ltr">Complex EH without atypia</td><td class="s1" dir="ltr">4%</td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td></tr><tr style="height: 20px"><th id="1499313419R39" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">40</div></th><td class="s2" dir="ltr">EH with atypia</td><td class="s1" dir="ltr">40%</td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td></tr></tbody></table></div>